Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis

Diabetes and Metabolism

Volumn 43, Issue 1, 2017, Pages 1-8

  Barkas, F ^a   Elisaf, M ^a   Tsimihodimos, V ^a   Milionis, H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cerebrovascular; Diabetes; Dipeptidyl peptidase 4 inhibitors; Gliptins; Randomized trial; Stroke

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR;

CEREBROVASCULAR ACCIDENT; DATA EXTRACTION; DIABETIC PATIENT; DRUG SAFETY; EMBASE; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; MORBIDITY; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; STROKE;

DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; STROKE;

EID: 85007489154     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.10.006     Document Type: Review

References (48)

1. [1] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
2. [2] van Dieren, S., Beulens, J.W., van der Schouw, Y.T., Grobbee, D.E., Neal, B., The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17:Suppl. 1 (2010), S3–S8.
3. [3] Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
4. [4] Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., Keen, H., Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44:Suppl. 2 (2001), S14–S21.
5. [5] Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
6. [6] Ray, K.K., Seshasai, S.R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009), 1765–1772.
7. [7] Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
8. [8] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
9. [9] Wilcox, R., Bousser, M.G., Betteridge, D.J., Schernthaner, G., Pirags, V., Kupfer, S., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007), 865–873.
10. [10] Kernan, W.N., Viscoli, C.M., Furie, K.L., Young, L.H., Inzucchi, S.E., Gorman, M., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
11. [11] Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
12. [12] McIntosh, C.H., Demuth, H.U., Pospisilik, J.A., Pederson, R., Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. Regul Pept 128 (2005), 159–165.
13. [13] Darsalia, V., Larsson, M., Nathanson, D., Klein, T., Nystrom, T., Patrone, C., Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J Cereb Blood Flow Metab 35 (2015), 718–723.
14. [14] Higgins, J.P., Thompson, S.G., Spiegelhalter, D.J., A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 172 (2009), 137–159.
15. [15] Riley, R.D., Higgins, J.P., Deeks, J.J., Interpretation of random effects meta-analyses. BMJ, 342, 2011, d549.
16. [16] Barnett, A.H., Charbonnel, B., Donovan, M., Fleming, D., Chen, R., Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 28 (2012), 513–523.
17. [17] Barnett, A.H., Huisman, H., Jones, R., von Eynatten, M., Patel, S., Woerle, H.J., Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 382 (2013), 1413–1423.
18. [18] Bosi, E., Camisasca, R.P., Collober, C., Rochotte, E., Garber, A.J., Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30 (2007), 890–895.
19. [19] Chacra, A.R., Tan, G.H., Ravichandran, S., List, J., Chen, R., Investigators, C.V., Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 8 (2011), 150–159.
20. [20] DeFronzo, R.A., Hissa, M.N., Garber, A.J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32 (2009), 1649–1655.
21. [21] Frederich, R., McNeill, R., Berglind, N., Fleming, D., Chen, R., The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr, 4, 2012, 36.
22. [22] Hollander, P.L., Li, J., Frederich, R., Allen, E., Chen, R., Investigators, C.V., Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 8 (2011), 125–135.
23. [23] Kawamori, R., Inagaki, N., Araki, E., Watada, H., Hayashi, N., Horie, Y., et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 14 (2012), 348–357.
24. [24] Lewin, A.J., Arvay, L., Liu, D., Patel, S., von Eynatten, M., Woerle, H.J., Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 34 (2012), 1909e15–1919e15.
25. [25] Nowicki, M., Rychlik, I., Haller, H., Warren, M., Suchower, L., Gause-Nilsson, I., et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 65 (2011), 1230–1239.
26. [26] Pan, C.Y., Yang, W., Tou, C., Gause-Nilsson, I., Zhao, J., Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 28 (2012), 268–275.
27. [27] Pratley, R.E., Fleck, P., Wilson, C., Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab 16 (2014), 613–621.
28. [28] Rosenstock, J., Aguilar-Salinas, C., Klein, E., Nepal, S., List, J., Chen, R., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 25 (2009), 2401–2411.
29. [29] Rosenstock, J., Rendell, M.S., Gross, J.L., Fleck, P.R., Wilson, C.A., Mekki, Q., Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 11 (2009), 1145–1152.
30. [30] Taskinen, M.R., Rosenstock, J., Tamminen, I., Kubiak, R., Patel, S., Dugi, K.A., et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13 (2011), 65–74.
31. [31] Yoon, K.H., Steinberg, H., Teng, R., Golm, G.T., Lee, M., O'Neill, E.A., et al. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. Diabetes Obes Metab 14 (2012), 745–752.
32. [32] Yki-Jarvinen, H., Rosenstock, J., Duran-Garcia, S., Pinnetti, S., Bhattacharya, S., Thiemann, S., et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52-week randomized, double-blind study. Diabetes Care 36 (2013), 3875–3881.
33. [33] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
34. [34] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
35. [35] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
36. [36] Beckman, J.A., Creager, M.A., Libby, P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002), 2570–2581.
37. [37] Scheen, A.J., Cardiovascular effects of gliptins. Nat Rev Cardiol 10 (2013), 73–84.
38. [38] Monami, M., Ahren, B., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15 (2013), 112–120.
39. [39] Magkou, D., Tziomalos, K., Antidiabetic treatment, stroke severity and outcome. World J Diabetes 5 (2014), 84–88.
40. [40] Mita, T., Katakami, N., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care 39 (2016), 139–148.
41. [41] Mita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Onuma, T., Kuribayashi, N., et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care 39 (2016), 455–464.
42. [42] Oyama, J., Murohara, T., Kitakaze, M., Ishizu, T., Sato, Y., Kitagawa, K., et al. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial. PLoS Med, 13, 2016, e1002051.
43. [43] Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016 [Epub ahead of print].
44. [44] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
45. [45] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
46. [46] Kim, S.C., Glynn, R.J., Liu, J., Everett, B.M., Goldfine, A.B., Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol 51 (2014), 1015–1023.
47. [47] Wu, S., Hopper, I., Skiba, M., Krum, H., Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 32 (2014), 147–158.
48. [48] Savarese, G., Perrone-Filardi, P., D'Amore, C., Vitale, C., Trimarco, B., Pani, L., et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. Int J Cardiol 181 (2015), 239–244.